Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-NOTA-FAPI PET/CT in FAP-expressing Malignant Tumors
NCT05749302Phase 3
Key facts
- Status
- Recruiting
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Radiopharmaceutical
- Conditions
- cancer
01
Overview
Phase 3, open-label, single-arm trial of [18F]AlF-NOTA-FAPI-04 in cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Diagnostic value at 1 year. Started Jan 2023; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Al18F-NOTA-FAPI PET/CT
Single arm receiving Al18F-NOTA-FAPI injection and PET/CT scan
03
Who it enrols
Patients with suspected or clearly diagnosed malignant tumors expressing fibroblast-activated proteins. Pregnant or breastfeeding women are excluded.
04
Endpoints
Primary
Diagnostic value
Beyond the preview
Go deeper on NCT05749302.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749302.